Krystal Biotech, Inc. (KRYS) bonds
KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$298.55+0.65 (+0.22%)
Close on Nov 17, 2026Market cap $8.84BP/E 37.4Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Krystal Biotech reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in Krystal Biotech's 10-Q for the period ended Aug 8, 2017
| Issue | Coupon | Carrying value |
|---|---|---|
| Debt Instrument Note Purchase Agreement One Convertible at $4 a share | 6.00% | $2.44M |
| Debt Instrument Note Purchase Agreement One Related Party Convertible at $4 a share | – | $948.00K |
| Debt Instrument Note Purchase Agreement Two Related Party Convertible at $6 a share | – | $750.00K |
| Debt Instrument Note Purchase Agreements Related Party Convertible | – | $1.70M |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
See a number that looks wrong?